Home > Insider Trading > Filing (0001415889-24-001830)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534133	Calcimedica Inc.	CALC	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1306695	Sanderling Venture Partners Vi Co Investment Fund Lp	1300 S El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No
1306717	Sanderling Venture Partners Vi Lp	1300 S. El Camino Real Suite 203 San Mateo CA 94402	No	No	No	No
1429588	Vi Management Ventures Sanderling	1300 S El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No
1565862	Sanderling Ventures Vii, L.p.	1300 S. El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No
1678656	Sanderling Ventures Vii Annex Fund, L.p.	1300 S El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No
1993457	Vii Management Ventures Sanderling	1300 S. El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No
1993660	Sanderling Ventures Vii (Canada), L.p.	1300 S. El Camino Real Suite 203 San Mateo CA 94402	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-23	243,356	$3.70	946,744	No	4	P	Direct
Common Stock	Acquisiton	2024-01-23	144,676	$3.70	727,433	No	4	P	Indirect	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock	Acquisiton	2024-01-23	194,472	$3.70	435,148	No	4	P	Indirect	By Sanderling Ventures VII, L.P.
Common Stock	Acquisiton	2024-01-23	51,032	$3.70	114,260	No	4	P	Indirect	By Sanderling Ventures VII (Canada), L.P.
Common Stock	Acquisiton	2024-01-23	13,184	$3.70	27,609	No	4	P	Indirect	By Sanderling Ventures VII Annex Fund, L.P.
Common Stock	Acquisiton	2024-01-23	3,920	$3.70	21,602	No	4	P	Indirect	By Sanderling Ventures Management VI
Common Stock	Acquisiton	2024-01-23	28,744	$3.70	30,292	No	4	P	Indirect	By Sanderling Ventures Management VII

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
No	4	P	Indirect	By Sanderling Ventures VII, L.P.
No	4	P	Indirect	By Sanderling Ventures VII (Canada), L.P.
No	4	P	Indirect	By Sanderling Ventures VII Annex Fund, L.P.
No	4	P	Indirect	By Sanderling Ventures Management VI
No	4	P	Indirect	By Sanderling Ventures Management VII

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant	Acquisiton	2024-01-23	121,678	$0.13	121,678	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	121,678	$0.13	121,678	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	72,338	$0.13	72,338	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	72,338	$0.13	72,338	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	97,236	$0.13	97,236	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	97,236	$0.13	97,236	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	25,516	$0.13	25,516	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	25,516	$0.13	25,516	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	6,592	$0.13	6,592	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	6,592	$0.13	6,592	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	1,960	$0.13	1,960	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	1,960	$0.13	1,960	$7.15
Common Stock	Warrant	Acquisiton	2024-01-23	14,372	$0.13	14,372	$5.36
Common Stock	Warrant	Acquisiton	2024-01-23	14,372	$0.13	14,372	$7.15

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
121,678	2024-01-23	2024-12-31	No	4	P	Direct
121,678	2024-01-23	2026-12-31	No	4	P	Direct
72,338	2024-01-23	2024-12-31	No	4	P	Indirect
72,338	2024-01-23	2026-12-31	No	4	P	Indirect
97,236	2024-01-23	2024-12-31	No	4	P	Indirect
97,236	2024-01-23	2026-12-31	No	4	P	Indirect
25,516	2024-01-23	2024-12-31	No	4	P	Indirect
25,516	2024-01-23	2026-12-31	No	4	P	Indirect
6,592	2024-01-23	2024-12-31	No	4	P	Indirect
6,592	2024-01-23	2026-12-31	No	4	P	Indirect
1,960	2024-01-23	2024-12-31	No	4	P	Indirect
1,960	2024-01-23	2026-12-31	No	4	P	Indirect
14,372	2024-01-23	2024-12-31	No	4	P	Indirect
14,372	2024-01-23	2026-12-31	No	4	P	Indirect

Footnotes

The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.